{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-24-006383","form_type":"8-K","ticker":"GKOS","cik":"0001192448","company_name":"GLAUKOS Corp","filed_at":"2024-05-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:17.570352+00:00","generated_at":"2026-06-03T02:12:04.684601+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Record Q1 net sales of $85.6M (+16% YoY); raised 2024 guidance to $357-$365M","bullets":["Glaucoma segment sales $67.2M (+20% YoY); Corneal Health $18.4M (+4% YoY).","GAAP gross margin 76%; non-GAAP gross margin 83%.","GAAP net loss per share ($0.82); non-GAAP net loss per share ($0.70) includes $11.7M IPR&D charge.","Raised 2024 net sales guidance from $350-$360M to $357-$365M.","Cash and investments ~$279M at quarter end."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-24-006383","json":"https://secwatch.observer/filing/0001558370-24-006383.json","markdown":"https://secwatch.observer/filing/0001558370-24-006383.md","text":"https://secwatch.observer/filing/0001558370-24-006383.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1192448/000155837024006383/0001558370-24-006383-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1192448/000155837024006383/gkos-20240501x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T02:12:04.684601+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"c6d75046738a7059c6537ecfe463a084c578794b","claim":"GLAUKOS Corp reported first quarter ended March 31, 2024 results: revenue $85.6 million, net income ($40.8 million), EPS ($0.82) per diluted share. Guidance raised.","evidence_excerpt":"of glaucoma, corneal disorders and retinal diseases, today announced financial results for the first quarter ended March 31, 2024. Key highlights include: ● Record net sales of $85.6 million in Q1 2024 increased 16% year-over-year. ● Glaucoma record net sales of $67.2 million in Q1 2024 increased 20% year-over-year. ● Corneal Health net sales of $18.4 million in Q1","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1192448/000155837024006383/0001558370-24-006383-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2024"},{"label":"Revenue","value":"$85.6 million"},{"label":"Net income","value":"($40.8 million)"},{"label":"EPS","value":"($0.82) per diluted share"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}